ProCE Banner Activity

Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

Podcast Episodes

Listen as Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss the diagnosis and typical presenting symptoms of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as well as findings from recent phase III studies including NETTER-2 and CABINET. Notable clinical pearls regarding GEP-NET therapies and current guidelines for GEP-NET care and monitoring are also highlighted.

Released: October 17, 2024

Expiration: October 16, 2025

Share

Faculty

Thor R. Halfdanarson

Thor R. Halfdanarson, MD

Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, Minnesota

Jonathan Strosberg

Jonathan Strosberg, MD

Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Thor R. Halfdanarson, MD

Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, Minnesota

Thor R. Halfdanarson, MD: researcher: Advances Accelerator Applications (a Novartis Company), Camurus, Crinetics, Exelixis, ITM, Perspective Therapeutics, TerSera, Thermo Fisher Scientific; consultant/advisor/speaker: Camurus, ITM, Novartis.

Jonathan Strosberg, MD

Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, Florida

Jonathan Strosberg, MD: consultant/advisor/speaker: Boehringer Ingelheim, Exelixis.